Anti-CD68 antibody [RM1031],Abcam,AB303565

Product Specifications Anti-CD68 antibody [RM1031] (ab303565) is a recombinant rabbit multiclonal antibody which is comprised of multiple monoclonal antibodies targeting different epitopes and recapitulating the performance of a polyclonal. Each component clone was developed by Abcam using patented rabbit monoclonal antibody technology. Anti-CD68 antibody [RM1031] (ab303565) is validated for use in ICC/IF, IHC-Fr, IHC-P and WB in human, mouse and rat samples. Anti-CD68 antibody [RM1031] (ab303565) specifically detects CD68/ Macrosialin (UniProt ID: P34810; Molecular weight: 37kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL). Quality and Validation Abcams high quality manufacturing and validation processes ensure Anti-CD68 antibody [RM1031] (ab303565) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of anti-CD68 antibody [RM1031] (ab303565) has been confirmed by testing in knockout samples. Target Information CD68 is a transmembrane glycoprotein predominantly located on macrophages, crucial for phagocytosis and antigen presentation. It is involved in various pathological conditions, including neuroinflammatory diseases, by clearing cellular debris and regulating immune responses. CD68 expression is associated with several diseases involving macrophage activity, such as cancer, neuroinflammation, granular cell tumors, and histiocytic sarcoma. What are recombinant multiclonals? Recombinant multiclonals are a mixture of recombinant antibodies co-expressed from a library of heavy and light chains. They offer several advantages including: - The sensitivity of polyclonal antibodies by recognising multiple epitopes - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production View our range of recombinant multiclonal antibodies . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents .